Micardisplus

Telmisartan and Hydrochlorothiazide, the active ingredients in Micardisplus, are an Angiotensin II receptor blocker (ARB) and a thiazide diuretic presented as oral tablets for oral use. The combination is indicated for the management of hypertension in adult patients. GNH USA supplies Micardisplus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micardisplus is used to treat hypertension, a condition characterized by elevated arterial pressure, by targeting the renin‑angiotensin system and promoting diuresis. Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. Essential hypertension: provides sustained blood pressure control when monotherapy is insufficient. Secondary hypertension: assists in achieving target pressures in patients with underlying causes such as renal disease.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased frequency of urination - Electrolyte disturbances such as low potassium - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe allergic reactions (rash, swelling, anaphylaxis) - Acute kidney injury or worsening renal function - Hyperkalemia, especially when combined with potassium‑sparing agents - Significant drops in blood pressure (hypotension) - Pancreatitis or severe abdominal pain

Before initiating therapy, clinicians should assess renal function, electrolyte status, and blood pressure response. - Monitor blood pressure regularly: adjust therapy based on readings. - Check renal function and serum electrolytes: especially potassium and sodium. - Use caution in patients with hepatic impairment: dose adjustments may be needed. - Elderly patients may be more susceptible to hypotension and electrolyte shifts. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Micardisplus may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: combined use can lead to excessive potassium rise and renal dysfunction. Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and affect kidney function. - Lithium: increased lithium levels, risk of toxicity. - Rifampin or other CYP inducers: may reduce telmisartan plasma concentrations.